• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pharvaris N.V.

    6/10/25 6:52:08 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    6-K 1 6-k_agm_pr_announcement_.htm 6-K 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

    Commission File Number: 001-40010

    Pharvaris N.V.

    (Translation of registrant’s name into English)

    Emmy Noetherweg 2

     

    2333 BK Leiden

     

    The Netherlands
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.


    PHARVARIS N.V.

     

     

    On June 10, 2025, Pharvaris N.V. (the “Company”) issued a press release announcing its 2025 annual general meeting of shareholders to be held on June 27, 2025 and made available to its shareholders certain other materials in connection with such meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The materials made available to the Company’s shareholders are attached as Exhibits 99.2 and 99.3 hereto and are incorporated by reference herein. Exhibit 99.4 contains the Company’s Annual Report for the year ended December 31, 2024, which is furnished herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    PHARVARIS N.V.

     

     

    Date: June 10, 2025

    By:

    /s/ Berndt Modig

     

    Name:

    Berndt Modig

     

    Title:

    Chief Executive Officer

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press Release dated June 10, 2025.

    99.2

     

    Convening Notice, including Agenda and Explanatory Notes.

    99.3

     

    Voting Proxy

    99.4

     

    Pharvaris N.V. Annual Report for the year ended December 31, 2024 (prepared in accordance with IFRS-EU).

     


    Get the next $PHVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    6/11/2025$32.00Buy
    Guggenheim
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharvaris Announces Annual Meeting of Shareholders

      ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the "Investors" section of Pharv

      6/10/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

      Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolioClinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedemaEpidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagon

      6/2/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

      ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clin

      5/19/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

      ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

      11/15/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

      Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update

      9/12/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      6/10/25 6:52:08 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      5/13/25 4:06:04 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:51:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Financials

    Live finance-specific insights

    See more
    • Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

      CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

      9/5/24 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

      Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

      12/6/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

      Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

      12/8/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Pharvaris N.V. with a new price target

      Guggenheim initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $32.00

      6/11/25 7:54:51 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

      Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

      4/29/25 8:11:22 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Pharvaris N.V. with a new price target

      Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

      9/25/23 7:40:10 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 8:42:52 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 10:27:18 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/13/24 2:14:59 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care